GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.oxybutynin transdermaloxybutynin transdermal decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.oxycodoneoxycodone and prochlorperazine both increase sedation. Use Caution/Monitor.oxymorphoneoxymorphone and prochlorperazine both increase sedation. Use Caution/Monitor.paliperidonepaliperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.paliperidone and prochlorperazine both increase sedation. Use Caution/Monitor.pancuroniumpancuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.pancuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.papaveretumpapaveretum and prochlorperazine both increase sedation. Use Caution/Monitor.papaverineprochlorperazine and papaverine both increase sedation. Use Caution/Monitor.paroxetineparoxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.prochlorperazine and paroxetine both increase QTc interval. Use Caution/Monitor.pazopanibprochlorperazine and pazopanib both increase QTc interval. Use Caution/Monitor.pentazocinepentazocine and prochlorperazine both increase sedation. Use Caution/Monitor.pentobarbitalpentobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.perphenazineperphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.perphenazine and prochlorperazine both increase sedation. Use Caution/Monitor.phendimetrazineprochlorperazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, phendimetrazine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.phenobarbitalphenobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.phentermineprochlorperazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, phentermine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.phenylephrineprochlorperazine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, phenylephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.phenylephrine POprochlorperazine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .prochlorperazine, phenylephrine PO. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.pholcodineprochlorperazine and pholcodine both increase sedation. Use Caution/Monitor.pimozidepimozide and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.pimozide and prochlorperazine both increase sedation. Use Caution/Monitor.pirbuterolprochlorperazine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.porfimerprochlorperazine, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.posaconazoleprochlorperazine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.pralidoximepralidoxime decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.pralidoxime decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.primaquineprimaquine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.primidoneprimidone and prochlorperazine both increase sedation. Use Caution/Monitor.procarbazineprocarbazine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Excessive sedation.promethazineprochlorperazine and promethazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.promethazine and prochlorperazine both increase sedation. Use Caution/Monitor.propafenonepropafenone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.propanthelinepropantheline decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.propantheline decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.propofolpropofol and prochlorperazine both increase sedation. Use Caution/Monitor.propylhexedrineprochlorperazine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, propylhexedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.protriptylineprochlorperazine and protriptyline both increase QTc interval. Use Caution/Monitor.prochlorperazine and protriptyline both increase sedation. Use Caution/Monitor.pseudoephedrineprochlorperazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.quazepamquazepam and prochlorperazine both increase sedation. Use Caution/Monitor.quetiapineprochlorperazine and quetiapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and quetiapine both increase sedation. Use Caution/Monitor.quinidinequinidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.ramelteonprochlorperazine and ramelteon both increase sedation. Use Caution/Monitor.ranolazineprochlorperazine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.rapacuroniumrapacuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.rapacuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rimabotulinumtoxinBprochlorperazine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.risperidoneprochlorperazine and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.prochlorperazine and risperidone both increase sedation. Use Caution/Monitor.rocuroniumrocuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.rocuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.salmeterolprochlorperazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.scopolaminescopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.scopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.scullcapprochlorperazine and scullcap both increase sedation. Use Caution/Monitor.secobarbitalsecobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidateprochlorperazine, serdexmethylphenidate/dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.sertralinesertraline and prochlorperazine both decrease QTc interval. Use Caution/Monitor.sevofluranesevoflurane and prochlorperazine both increase sedation. Use Caution/Monitor.sevoflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor.shepherd's purseprochlorperazine and shepherd's purse both increase sedation. Use Caution/Monitor.siponimodsiponimod and prochlorperazine both decrease QTc interval. Use Caution/Monitor.smokingsmoking decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.solifenacinsolifenacin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.stiripentolstiripentol, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.sufentanilsufentanil and prochlorperazine both increase sedation. Use Caution/Monitor.sulfamethoxazoleprochlorperazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.sunitinibsunitinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.tacrolimustacrolimus and prochlorperazine both decrease QTc interval. Use Caution/Monitor.tapentadoltapentadol and prochlorperazine both increase sedation. Use Caution/Monitor.teduglutideteduglutide increases levels of prochlorperazine by Other (see comment). Use Caution/Monitor. Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.telavancinprochlorperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamtemazepam and prochlorperazine both increase sedation. Use Caution/Monitor.terbutalineprochlorperazine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tetrabenazineprochlorperazine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.thioridazineprochlorperazine and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and thioridazine both increase sedation. Use Caution/Monitor.thiothixeneprochlorperazine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and thiothixene both increase sedation. Use Caution/Monitor.tiotropiumtiotropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.tiotropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tobacco usetobacco use decreases levels of prochlorperazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.tolterodinetolterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.tolterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.topiramateprochlorperazine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and prochlorperazine both increase sedation. Use Caution/Monitor.trazodoneprochlorperazine and trazodone both increase QTc interval. Use Caution/Monitor.prochlorperazine and trazodone both increase sedation. Use Caution/Monitor.triazolamtriazolam and prochlorperazine both increase sedation. Use Caution/Monitor.triclofostriclofos and prochlorperazine both increase sedation. Use Caution/Monitor.trifluoperazineprochlorperazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and trifluoperazine both increase sedation. Use Caution/Monitor.trihexyphenidyltrihexyphenidyl decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimprochlorperazine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipramineprochlorperazine and trimipramine both increase QTc interval. Use Caution/Monitor.prochlorperazine and trimipramine both increase sedation. Use Caution/Monitor.triprolidinetriprolidine and prochlorperazine both increase sedation. Use Caution/Monitor.tropisetronprochlorperazine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chloridetrospium chloride decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.trospium chloride decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.valbenazinevalbenazine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.vecuroniumvecuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.vecuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.venlafaxinevenlafaxine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.prochlorperazine and venlafaxine both increase QTc interval. Use Caution/Monitor.voriconazoleprochlorperazine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.vorinostatvorinostat and prochlorperazine both decrease QTc interval. Use Caution/Monitor.xylometazolineprochlorperazine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, xylometazoline. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.yohimbineprochlorperazine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, yohimbine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.ziconotideprochlorperazine and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneprochlorperazine and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and ziprasidone both increase sedation. Use Caution/Monitor.zolpidemprochlorperazine will increase the level or effect of zolpidem by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Additive effect of decreased alertness and psychomotor performancezotepineprochlorperazine and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and zotepine both increase sedation. Use Caution/Monitor.Minor (60)amiodaroneamiodarone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.amitriptylineamitriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapineamoxapine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amoxapine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.asenapineasenapine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.atropineprochlorperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMprochlorperazine increases toxicity of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.benazeprilprochlorperazine increases effects of benazepril by unspecified interaction mechanism. Minor/Significance Unknown. Enhanced hypotensive effects.brimonidinebrimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.captoprilprochlorperazine increases effects of captopril by unspecified interaction mechanism. Minor/Significance Unknown.celecoxibcelecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.chasteberrychasteberry decreases effects of prochlorperazine by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).chloroquinechloroquine will increase the level or effect of prochlorperazine by affecting hepatic enzyme